Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features

NCT01351896 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01351896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01351896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 2, 2011
Completion date
May 6, 2027
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage i small lymphocytic lymphoma, ann arbor stage ii small lymphocytic lymphoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia with unmutated immunoglobulin heavy chain variable-region gene, small lymphocytic lymphoma, small lymphocytic lymphoma with unmutated immunoglobulin heavy chain variable-region gene, stage 0 chronic lymphocytic leukemia, stage i chronic lymphocytic leukemia, stage ii chronic lymphocytic leukemia